Renal Reinforcements: Slowing Diabetic Kidney Disease with Multiple New Agents.
作者信息
Thomas Robert L, Rifkin Dena E
机构信息
Division of Endocrinology, University of California, San Diego and Veterans Affairs Healthcare System, San Diego, California.
Division of Nephrology, University of California, San Diego and Veterans Affairs Healthcare System, San Diego, California.
出版信息
J Am Soc Nephrol. 2024 Jul 30;35(9):1143-5. doi: 10.1681/ASN.0000000000000458.
Abstract
摘要
相似文献
1
Renal Reinforcements: Slowing Diabetic Kidney Disease with Multiple New Agents.肾脏强化治疗：多种新型药物延缓糖尿病肾病进展
J Am Soc Nephrol. 2024 Jul 30;35(9):1143-5. doi: 10.1681/ASN.0000000000000458.
2
Analysis of urine Raman spectra differences from patients with diabetes mellitus and renal pathologies.分析糖尿病及肾脏病变患者尿液的拉曼光谱差异。
PeerJ. 2023 Feb 27;11:e14879. doi: 10.7717/peerj.14879. eCollection 2023.
3
Perirenal fat and chronic kidney disease in type 2 diabetes: The mediation role of afferent arteriolar resistance.2型糖尿病患者肾周脂肪与慢性肾脏病：入球小动脉阻力的中介作用
Diabetes Metab. 2024 Nov;50(6):101583. doi: 10.1016/j.diabet.2024.101583. Epub 2024 Oct 9.
4
The Ability of AST-120 to Lower the Serum Indoxyl Sulfate Level Improves Renal Outcomes and the Lipid Profile in Diabetic and Nondiabetic Animal Models of Chronic Kidney Disease: A Meta-Analysis.AST-120降低血清硫酸吲哚酚水平的能力改善慢性肾脏病糖尿病和非糖尿病动物模型的肾脏结局及脂质谱：一项荟萃分析
Toxins (Basel). 2024 Dec 16;16(12):544. doi: 10.3390/toxins16120544.
5
A renaissance in the treatment of diabetic kidney disease, hypertension in chronic kidney disease, and beyond.糖尿病肾病、慢性肾病高血压及其他疾病治疗的复兴。
J Osteopath Med. 2021 Oct 15;122(1):55-63. doi: 10.1515/jom-2021-0150.
6
Effect of renin-angiotensin-aldosterone system blockade in adults with diabetes mellitus and advanced chronic kidney disease not on dialysis: a systematic review and meta-analysis.肾素-血管紧张素-醛固酮系统阻断剂在未接受透析的糖尿病合并晚期慢性肾脏病成人患者中的作用：系统评价和荟萃分析。
Nephrol Dial Transplant. 2018 Jan 1;33(1):12-22. doi: 10.1093/ndt/gfx072.
7
Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021.成人糖尿病肾脏疾病患者的高血压和肾素-血管紧张素-醛固酮系统阻滞剂管理：英国临床糖尿病学家协会和英国肾脏协会 2021 年指南更新。
BMC Nephrol. 2022 Jan 3;23(1):9. doi: 10.1186/s12882-021-02587-5.
8
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome.司美格鲁肽：治疗心血管-肾脏-代谢综合征的关键药物。
Future Cardiol. 2025 Jul;21(9):663-683. doi: 10.1080/14796678.2025.2511412. Epub 2025 Jun 3.
9
Effect of pentoxifylline on renal outcomes in chronic kidney disease patients: A systematic review and meta-analysis.己酮可可碱对慢性肾脏病患者肾脏结局的影响：系统评价和荟萃分析。
Pharmacol Res. 2016 May;107:315-332. doi: 10.1016/j.phrs.2016.03.001. Epub 2016 Mar 17.
10
Performance of the Kidney Failure Risk Equation according to diabetic status in the CKD-CAREMEAU cohort of patients with chronic kidney disease.根据慢性肾脏病CKD-CAREMEAU队列中患者的糖尿病状态，评估肾衰竭风险方程的性能。
J Nephrol. 2025 Jun 19. doi: 10.1007/s40620-025-02286-6.
本文引用的文献
1
Effect of Avenciguat on Albuminuria in Patients with CKD: Two Randomized Placebo-Controlled Trials.阿文西呱对慢性肾脏病患者蛋白尿的影响：两项随机安慰剂对照试验
J Am Soc Nephrol. 2024 May 25;35(9):1227-39. doi: 10.1681/ASN.0000000000000418.
2
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.司美格鲁肽对 2 型糖尿病患者慢性肾脏病的影响。
N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24.
3
Renoprotective effects of GLP-1 receptor agonists and SGLT-2 inhibitors-is hemodynamics the key point?GLP-1 受体激动剂和 SGLT-2 抑制剂的肾保护作用——血流动力学是关键吗？
Am J Physiol Cell Physiol. 2023 Jul 1;325(1):C243-C256. doi: 10.1152/ajpcell.00147.2023. Epub 2023 Jun 5.
4
GLP-1 Promotes Cortical and Medullary Perfusion in the Human Kidney and Maintains Renal Oxygenation During NaCl Loading.GLP-1 可促进人肾脏皮质和髓质灌注，并在 NaCl 负荷期间维持肾脏氧合。
J Am Heart Assoc. 2023 Feb 7;12(3):e027712. doi: 10.1161/JAHA.122.027712. Epub 2023 Feb 3.
5
GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions.糖尿病肾病中的胰高血糖素样肽-1受体激动剂：当前证据与未来方向
Kidney Res Clin Pract. 2022 Mar;41(2):136-149. doi: 10.23876/j.krcp.22.001. Epub 2022 Mar 25.
6
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.非奈利酮对 2 型糖尿病患者慢性肾脏病结局的影响。
N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.
7
The tubular hypothesis of nephron filtration and diabetic kidney disease.管状假说在肾单位滤过和糖尿病肾病中的作用。
Nat Rev Nephrol. 2020 Jun;16(6):317-336. doi: 10.1038/s41581-020-0256-y. Epub 2020 Mar 9.
8
Diabetic Kidney Disease: Challenges, Progress, and Possibilities.糖尿病肾病：挑战、进展与可能。
Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2032-2045. doi: 10.2215/CJN.11491116. Epub 2017 May 18.
9
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.恩格列净与 2 型糖尿病患者的肾脏疾病进展。
N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14.
10
Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study.糖尿病控制与并发症试验/糖尿病干预及并发症流行病学研究中的肾脏疾病及相关发现
Diabetes Care. 2014;37(1):24-30. doi: 10.2337/dc13-2113.
Zotero 插件